ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biologics

AGC triples US biologics capacity

by Jean-François Tremblay
January 7, 2019 | APPEARED IN VOLUME 97, ISSUE 1

 

AGC, formerly Asahi Glass, will spend $80 million to triple its US production capacity for biopharmaceuticals. At its Seattle plant, the company will install 12 2,000-L single-use mammalian cell bioreactors. At the site, the firm will also set up its first US microbial cell manufacturing facilities. AGC is boosting its biotech drug contract manufacturing business as part of a plan to raise its sales in the life sciences sector to $800 million by 2025. It bought two contract manufacturers recently: the German firm Biomeva in 2016 and Denmark’s CMC Biologics in 2017.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment